Graham has over 20 years of drug discovery experience gained in small to medium sized biopharma companies and in academia. His work at the University of Oxford has encompassed multiple therapeutic areas, including oncology, muscular dystrophy and regenerative medicine and he has co-founded several companies including MuOx (acquired by Summit Therapeutics) and OxStem Neuro.
Prior to this Graham established and led the medicinal chemistry team at Summit Therapeutics which discovered ezutromid, a potential first-in-class treatment for Duchenne Muscular Dystrophy which progressed to Phase 2 clinical trials. In his previous role at OSI Pharmaceuticals Inc his group were responsible for the discovery of OSI-930, a dual kit-KDR kinase inhibitor which progressed into Phase 1 clinical trials. Graham gained his PhD in Chemistry from the University of Nottingham. He has co-authored multiple papers and is an inventor on 40 patents or patent applications.